Lipids and lipid-based formulations: optimizing the oral delivery of lipophilic drugs
The DOI matches its Crossref record; 253 of the 253 references it cites were found in a registry or an index.
Abstract
Highly potent, but poorly water-soluble, drug candidates are common outcomes of contemporary drug discovery programmes and present a number of challenges to drug development - most notably, the issue of reduced systemic exposure after oral administration. However, it is increasingly apparent that formulations containing natural and/or synthetic lipids present a viable means for enhancing the oral bioavailability of some poorly water-soluble, highly lipophilic drugs. This Review details the mechanisms by which lipids and lipidic excipients affect the oral absorption of lipophilic drugs and provides a perspective on the possible future applications of lipid-based delivery systems. Particular emphasis has been placed on the capacity of lipids to enhance drug solubilization in the intestinal milieu, recruit intestinal lymphatic drug transport (and thereby reduce first-pass drug metabolism) and alter enterocyte-based drug transport and disposition.
Overview
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“Conventional absorption and bioavailability assessments, and the body-weight regressions built upon them, implicitly assume the portal route and seldom quantify the lymphatic contribution, even though, for suitable compounds, it can represent a substantial fraction of systemic exposure [29,30].”
From Beyond Body Weight: A Comprehensive Review of Allometric Scaling in Drug Development for Human Dose Predictions (2026) · cites this paper as [29]
In the citing paper
“This route becomes quantitatively relevant only for compounds that combine high lipophilicity with appreciable long-chain triglyceride solubility, for which a log P greater than 5 and a lipid solubility above approximately 50 mg/g are commonly cited as approximate thresholds [29,30].”
From Beyond Body Weight: A Comprehensive Review of Allometric Scaling in Drug Development for Human Dose Predictions (2026) · cites this paper as [29]
In the citing paper
“Because lymphatic delivery reaches the systemic circulation while bypassing hepatic first-pass metabolism, it can materially increase the oral bioavailability of affected compounds and lower their apparent first-pass loss in a manner that a body-weight regression of systemic clearance or volume cannot anticipate [28,29,30].”
From Beyond Body Weight: A Comprehensive Review of Allometric Scaling in Drug Development for Human Dose Predictions (2026) · cites this paper as [29]
In the citing paper
“For highly lipophilic drugs, a fraction of the absorbed dose can bypass the portal circulation entirely and reach the systemic circulation via the intestinal lymphatics, associated with triglyceride-rich lipoproteins (chylomicrons) assembled within the enterocyte [28,29].”
From Beyond Body Weight: A Comprehensive Review of Allometric Scaling in Drug Development for Human Dose Predictions (2026) · cites this paper as [29]
In the citing paper
“The extent of transport is highly sensitive to prandial state and to the type and quantity of co-administered lipid, which differ across preclinical study designs and between the fasted conditions typical of first-in-human protocols and the fed conditions under which lymphatic transport is greatest [29,30].”
From Beyond Body Weight: A Comprehensive Review of Allometric Scaling in Drug Development for Human Dose Predictions (2026) · cites this paper as [29]
Citations
Cites
Arzneimittelforschung: Erstanwendung am Menschen in der Phase I
Miletzki, B., & Gleiter, C. H. (2005) · Bundesgesundheitsblatt Gesundheitsforsch.Gesundheitsschutz · doi:10.1007/s00103-005-1024-7 · Cited by 9,355
Drug-like properties and the causes of poor solubility and poor permeability
Lipinski, C. A. (2000) · Journal of Pharmacological and Toxicological Methods · doi:10.1016/s1056-8719(00)00107-6 · Cited by 3,734 · cited 1×
“This is especially the case when potent, but highly lipophilic, drug candidates arise from complex chemical scaffolds and multiple high-throughput activity screen”
BackgroundNuclear Receptors and Lipid Physiology: Opening the X-Files
Chawla, A., Repa, J. J., Evans, R. M., & Mangelsdorf, D. J. (2001) · Science · doi:10.1126/science.294.5548.1866 · Cited by 2,085
Apolipoprotein E: Far More Than a Lipid Transport Protein
Mahley, R. W., & Rall, S. C. (2000) · Annual Review of Genomics and Human Genetics · doi:10.1146/annurev.genom.1.1.507 · Cited by 1,836
Berge, K. E., Tian, H., Graf, G. A., Yu, L., Grishin, N. V., Schultz, J., Kwiterovich, P., Shan, B., Barnes, R., & Hobbs, H. H. (2000) · Science · doi:10.1126/science.290.5497.1771 · Cited by 1,648
Niemann-Pick C1 Like 1 Protein Is Critical for Intestinal Cholesterol Absorption
Altmann, S. W., Davis, H. R., Zhu, L.-J., Yao, X., Hoos, L. M., Tetzloff, G., Iyer, S. P. N., Maguire, M., Golovko, A., Zeng, M., et al. (2004) · Science · doi:10.1126/science.1093131 · Cited by 1,577
Smit, J. J. M., Schinkel, A. H., Elferink, R. P. J. O., Groen, A. K., Wagenaar, E., van Deemter, L., Mol, C. A. A. M., Ottenhoff, R., van der Lugt, N. M. T., van Roon, M. A., et al. (1993) · Cell · doi:10.1016/0092-8674(93)90380-9 · Cited by 1,456
Wu, C.-Y., & Benet, L. Z. (2005) · Pharmaceutical Research · doi:10.1007/s11095-004-9004-4 · Cited by 1,401 · cited 1×
“In addition to the potential effect of lipidic excipients (primarily surfactants) on P-gp-mediated efflux, Benet and co-workers have recently suggested that high-fat meals could inhibit P-g”
BackgroundSelf-emulsifying drug delivery systems (SEDDS) for improved oral delivery of lipophilic drugs
Neslihan Gursoy, R., & Benita, S. (2004) · Biomedicine & Pharmacotherapy · doi:10.1016/j.biopha.2004.02.001 · Cited by 1,358
Regulation of Absorption and ABC1-Mediated Efflux of Cholesterol by RXR Heterodimers
Repa, J. J., Turley, S. D., Lobaccaro, J.-M. A., Medina, J., Li, L., Lustig, K., Shan, B., Heyman, R. A., Dietschy, J. M., & Mangelsdorf, D. J. (2000) · Science · doi:10.1126/science.289.5484.1524 · Cited by 1,301
Cited by
Items 901–1,000 of 1,003
Dietary Protective Potential of Fucoxanthin as an Active Food Component on Neurological Disorders
Chen, Y., Lü, H., Ding, Y., Liu, S., Ding, Y., Lu, B., Xiao, J., & Zhou, X. (2023) · Journal of Agricultural and Food Chemistry · doi:10.1021/acs.jafc.2c08249 · Cited by 29
Structure Modification: a Successful Tool for Prodrug Design
Cheng, Y., Zhong, C., Yan, S., Chen, C., & Gao, X. (2023) · Future Medicinal Chemistry · doi:10.4155/fmc-2022-0309 · Cited by 29
Design of high-loading and high-stability viscoelastic emulsions for polymethoxyflavones
Ting, Y., Xia, Q., Li, S., Ho, C., & Huang, Q. (2013) · Food Research International · doi:10.1016/j.foodres.2013.07.047 · Cited by 29
Sadhukha, T., Layek, B., & Prabha, S. (2017) · Drug Delivery and Translational Research · doi:10.1007/s13346-017-0383-6 · Cited by 29
“The rate of lipid digestion was estimated from the time and volume of NaOH used for the lipolysis as described in previous reports [22].”
BackgroundMethodInfluentialSunazuka, Y., Ueda, K., Higashi, K., Tanaka, Y., & Moribe, K. (2018) · International Journal of Pharmaceutics · doi:10.1016/j.ijpharm.2018.05.031 · Cited by 29
Dening, T. J., Thomas, N., Rao, S., Looveren, C. V., Cuyckens, F., Holm, R., & Prestidge, C. A. (2018) · Molecular Pharmaceutics · doi:10.1021/acs.molpharmaceut.8b00555 · Cited by 29
Porous Starch and Its Applications
Liu, L., Shen, W., Zhang, W., Li, F., & Zhu, Z. (2018) · Springer eBooks · doi:10.1007/978-981-13-1077-5_4 · Cited by 29
El-Laithy, H. M., Badawi, A. A. E.-L., Abdelmalak, N. S., & Elsayyad, N. M. E. (2019) · European Journal of Pharmaceutical Sciences · doi:10.1016/j.ejps.2019.06.008 · Cited by 29
“This would therefore, facilitate the penetration of CB across the endothelial cell membrane and its internalization inside the tissues by endocytosis resulting in increasing the uptake and absorption e ffi ciency (Porter et al., 2007; Yang et al., 2011).”
BackgroundYe, J., Wu, H., Huang, C., Lin, W.-T., Zhang, C., Huang, B., Lu, B., Xu, H., Li, X., & Long, X. (2019) · International Journal of Nanomedicine · doi:10.2147/ijn.s203911 · Cited by 29
“Free drug dispersed in the aqueous phase is either transported by passive diffusion (a) or by carrier-mediated uptake in the dissociated state (b).(16) The upper lipid phase contained”
BackgroundYu, Z., Fan, W., Wang, L., He, H., Lv, Y., Qi, J., Lü, Y., & Wu, W. (2019) · Biomaterials Science · doi:10.1039/c9bm00873j · Cited by 29
Potharaju, S., Mutyam, S. K., Liu, M., Green, C., Frueh, L., Nilsen, A., Pou, S., Winter, R. W., Riscoe, M. K., & Shankar, G. N. (2020) · Pharmaceutical Development and Technology · doi:10.1080/10837450.2020.1725893 · Cited by 29
“…(Elamin et al. 1994; Jinno et al. 2006), (b) amorphous solid dispersions (Vasconcelos et al. 2007), (c) co-crystal formation (Aakeroy et al. 2009; Smith et al. 2011), (d) complexation (Kimura et al. 2000), (e) co-solvent (Yalkowsky and Rubino 1985), and (f) lipid-based systems (Porter et al. 2007).”
Gastrointestinal Dissolution and Absorption of Class II Drugs
Dahan, A., & Amidon, G. L. (2008) · Methods and principles in medicinal chemistry · doi:10.1002/9783527623860.ch3 · Cited by 29
The Impact of Lymphatic Transport on the Systemic Disposition of Lipophilic Drugs
Caliph, S. M., Cao, E., Bulitta, J. B., Hu, L., Han, S., Porter, C. J. H., & Trevaskis, N. L. (2013) · Journal of Pharmaceutical Sciences · doi:10.1002/jps.23597 · Cited by 29
Self-citationZhang, X., Sun, D., Wei, X., Xia, X., Fang, Z., Ren, M., & Lou, H. (2014) · International Journal of Nanomedicine · doi:10.2147/ijn.s63777 · Cited by 29
“28,30 The chylomicron flow-blocking rat model was an efficient tool for evaluating lymphatic absorption.”
Wang, M., Xie, T., Chang, Z., Wang, L., Xie, X., Kou, Y., Xu, H., & Gao, X. (2015) · PLoS ONE · doi:10.1371/journal.pone.0143625 · Cited by 29
“Additionally, as reported, sodium deoxycholate incorporated into the proliposomal formulation can facilitate liposome formation so that lipids containing bile salts can readily transform into vesicular or mixed micelles in the gastrointestinal environment[20, 21, 22].”
BackgroundPatel, P., Pailla, S. R., Rangaraj, N., Cheruvu, H. S., Dodoala, S., & Sampathi, S. (2019) · AAPS PharmSciTech · doi:10.1208/s12249-018-1214-x · Cited by 29
Dening, T. J., Joyce, P. M., Webber, J. L., Beattie, D. A., & Prestidge, C. A. (2018) · Journal of Colloid and Interface Science · doi:10.1016/j.jcis.2018.08.015 · Cited by 28
Lee, G., Han, S., Lu, Z., Hong, J., Phillips, A. R. J., Windsor, J. A., Porter, C. J. H., & Trevaskis, N. L. (2021) · International Journal of Pharmaceutics · doi:10.1016/j.ijpharm.2021.120247 · Cited by 28
Self-citationRyšánek, P., Grus, T., Lukáč, P., Kozlík, P., Křížek, T., Pozniak, J., Roušarová, J., Královičová, J., Canová, N. K., Boleslavská, T., et al. (2021) · British Journal of Pharmacology · doi:10.1111/bph.15644 · Cited by 28
“Upon absorption into intestinal mucosa, highly lipophilic compounds are typically incorporated into chylomicrons and secreted into mesenteric lymph, which is drained into systemic circulation by a system of lymphatic vessels (Charman & Stella, 1986; Porter et al., 2007).”
BackgroundSaladi, V. N., Raju, K. B., Mandad, P. R., Krishna, G. R., Sajja, E., Thirumali, R. S., Marutapilli, A., & Mathad, V. T. (2022) · Crystal Growth & Design · doi:10.1021/acs.cgd.1c01087 · Cited by 28
Feng, W., Qin, C., Abdelrazig, S., Bai, Z., Raji, M., Darwish, R., Chu, Y., Ji, L., Gray, D. A., Stocks, M. J., et al. (2022) · International Journal of Pharmaceutics · doi:10.1016/j.ijpharm.2022.121947 · Cited by 28
Xia, D., Hu, C., & Hou, Y. (2023) · European Journal of Pharmaceutics and Biopharmaceutics · doi:10.1016/j.ejpb.2023.02.016 · Cited by 29
Intestinal Transport as a Potential Determinant of Drug Bioavailability
Nauli, A. M., & Nauli, S. M. (2013) · Current Clinical Pharmacology · doi:10.2174/1574884711308030012 · Cited by 28
Assali, M., Cid, J., Leal, M. P., Muñoz-Bravo, M., Fernández, I., Wellinger, R. E., & Khiar, N. (2013) · ACS Nano · doi:10.1021/nn304986x · Cited by 28
Fundamental understanding of drug absorption from a parenteral oil depot
Kalicharan, R. W., Schot, P., & Vromans, H. (2015) · European Journal of Pharmaceutical Sciences · doi:10.1016/j.ejps.2015.12.011 · Cited by 28
Joyce, P. M., Kempson, I. M., & Prestidge, C. A. (2015) · Langmuir · doi:10.1021/acs.langmuir.5b02476 · Cited by 28
Zhou, X. W., Yang, Z., Chen, S., Han, S., Xu, X., Guo, J., Liu, M., Che, L., Li, X., & Zhang, J. (2016) · Biomacromolecules · doi:10.1021/acs.biomac.6b00512 · Cited by 28
ENHANCEMENT OF DISSOLUTION CHARACTERISTICS OF CLOPIDOGREL BISULPHATE BY PRONIOSOMES
Mazyed, E. A., & Zakaria, S. (2019) · International Journal of Applied Pharmaceutics · doi:10.22159/ijap.2019v11i2.30575 · Cited by 28
“Solvents used were chloroform and ethanol (2:1) because clopidogrel and lipids are soluble in this mixture and also ethanol is less toxic than methanol [11].”
MethodAcquistapace, S., Patel, L., Patin, A., Forbes-Blom, E., Cuenoud, B. M., & Wooster, T. J. (2019) · Food & Function · doi:10.1039/c9fo00671k · Cited by 28
Salim, M., Fraser‐Miller, S. J., Bērziņš, K., Sutton, J. J., Ramirez, G., Clulow, A. J., Hawley, A. M., Beilles, S., Gordon, K. C., & Boyd, B. J. (2020) · Molecular Pharmaceutics · doi:10.1021/acs.molpharmaceut.9b01149 · Cited by 28
Antifungal Activity of 2′-Hydroxychalcone Loaded in Nanoemulsion Against Paracoccidioides Spp.
Medina‐Alarcón, K. P., Singulani, J. D. L., Dutra, L. A., Pitangui, N. D. S., Pereira-da-Silva, M. A., dos Santos, M. B., Ayusso, G. M., Regasini, L. O., Soares, C. P., Chorilli, M., et al. (2020) · Future Microbiology · doi:10.2217/fmb-2019-0095 · Cited by 28
Molecular Dynamics Simulations of Glycocholate−Oleic Acid Mixed Micelle Assembly
Turner, D. C., Yin, F., Kindt, J. T., & Zhang, H. (2010) · Langmuir · doi:10.1021/la903573m · Cited by 28
Ritonavir loaded solid lipid nanoparticles for oral drug delivery and bioavailability enhancement
Chettupalli, A. K., Bukke, S. P. N., Rahaman, S. A., Unnisa, A., Adepu, M., Kavitha, M., Babu, M. R., Narapureddy, B. R., & Onohuean, H. (2025) · Discover Applied Sciences · doi:10.1007/s42452-024-06322-1 · Cited by 27
“However, due to its restricted capacity to dissolve in water, its effectiveness can vary [12, 13, 24].”
Supramolecular hydrophobic guest transport system based on pillar[5]arene
Qi, Z., Achazi, K., Haag, R., Dong, S., & Schalley, C. A. (2015) · Chemical Communications · doi:10.1039/c5cc03955j · Cited by 27
A Comprehensive Review on Self-Nano Emulsifying Drug Delivery Systems: Advancements and Applications
Sokkula, S. R., & Suresh, G. (2020) · International Journal of Pharmaceutical Sciences and Drug Research · doi:10.25004/ijpsdr.2020.120522 · Cited by 27
“” The addition of co-surfactants into SNEDDS is not obligatory for most non-ionic surfactants.[23] In SNEDDS, the co-surfactants with HLB values ranging between 10 and 14 are used.”
A COMPREHENSIVE REVIEW ON SUPERSATURABLE SELF-NANOEMULSIFYING DRUG DELIVERY SYSTEM
Reddy, M. R., & Gubbiyappa, K. S. (2021) · Asian Journal of Pharmaceutical and Clinical Research · doi:10.22159/ajpcr.2021.v14i8.41987 · Cited by 27
Seo, E. B., Plessis, D., & Viljoen, J. M. (2022) · Pharmaceuticals · doi:10.3390/ph15020120 · Cited by 27
“This amount of lipid equates to only two capsules containing a lipid-based formulation to be administered in the fasted state, which is deemed ample to attain the anticipated physiological response [78].”
BackgroundInfluentialJohannesson, J., Pathare, M. M., Johansson, M., Bergström, C. A. S., & Teleki, A. (2023) · Journal of Colloid and Interface Science · doi:10.1016/j.jcis.2023.07.055 · Cited by 27
Early evaluation of opportunities in oral delivery of PROTACs to overcome their molecular challenges
Yang, W., Saboo, S., Zhou, L., Askin, S., & Bak, A. (2023) · Drug Discovery Today · doi:10.1016/j.drudis.2023.103865 · Cited by 27
Gul, S., Miano, T. F., Mujeeb, A., Chachar, M., Majeedano, M. I., Murtaza, G., Ahmed, W., Khanzada, Y. A., & Ansari, M. (2024) · Matrix Science Pharma · doi:10.4103/mtsp.mtsp_1_24 · Cited by 27
Predicting the Effect of Fed-State Intestinal Contents on Drug Dissolution
Uzun, E. D. G., Ashtikar, M., Crison, J. R., Woltosz, W. S., Bolger, M. B., & Carrier, R. L. (2010) · Pharmaceutical Research · doi:10.1007/s11095-010-0264-x · Cited by 27
“Fats in food are also digested and form vesicles and emulsions (3).”
BackgroundBile salt/phospholipid mixed micelle precursor pellets prepared by fluid-bed coating
Lü, Y., Dong, Xie, Y., Qi, J., Hu, F., Li, & Wu, W. (2013) · International Journal of Nanomedicine · doi:10.2147/ijn.s42349 · Cited by 27
“16 In this case, the MMs act as a drug reservoir and the encapsulated drugs are released constantly in the brush border.”
InfluentialImproving intracellular uptake of 5-demethyltangeretin by food grade nanoemulsions
Zheng, J., Li, Y., Song, M., Fang, X., Cao, Y., McClements, D. J., & Xiao, H. (2014) · Food Research International · doi:10.1016/j.foodres.2014.02.013 · Cited by 27
Crum, M., Trevaskis, N. L., Pouton, C. W., & Porter, C. J. H. (2017) · Molecular Pharmaceutics · doi:10.1021/acs.molpharmaceut.6b00792 · Cited by 27
Self-citationSantander-Ortega, M. J., Plaza-Oliver, M., Robledo, V. R., Castro‐Vázquez, L., Villaseca-González, N., González-Fuentes, J., Cano, E. L., Marcos, P., Lozano, M. V., & Jiménez, M. D. M. A. (2017) · Langmuir · doi:10.1021/acs.langmuir.7b00351 · Cited by 27
Joyce, P. M., Yasmin, R., Bhatt, A., Boyd, B. J., Pham, A. C., & Prestidge, C. A. (2017) · Molecular Pharmaceutics · doi:10.1021/acs.molpharmaceut.7b00676 · Cited by 27
Chen, Y., Okur, H. İ., Lütgebaucks, C., & Roke, S. (2017) · Langmuir · doi:10.1021/acs.langmuir.7b02896 · Cited by 27
Characterization of Gastrointestinal Fate of Nanoemulsions
Zhang, R., & McClements, D. J. (2018) · Elsevier eBooks · doi:10.1016/b978-0-12-811838-2.00018-7 · Cited by 27
Joyce, P. M., & Prestidge, C. A. (2018) · European Journal of Pharmaceutical Sciences · doi:10.1016/j.ejps.2018.03.018 · Cited by 27
van Marion, D. M. S., Hu, X., Zhang, D., Hoogstra‐Berends, F., Seerden, J.-P. G., Loen, L., Heeres, A., Steen, H., Henning, R. H., & Brundel, B. J. J. M. (2019) · Drug Design Development and Therapy · doi:10.2147/dddt.s176924 · Cited by 27
Wooster, T. J., Acquistapace, S., Mettraux, C., Donato, L., & Dekkers, B. L. (2019) · Journal of Colloid and Interface Science · doi:10.1016/j.jcis.2019.06.033 · Cited by 27
Jyotshna, Gupta, A. C., Bawankule, D. U., Verma, A. K., & Shanker, K. (2020) · Journal of Drug Delivery Science and Technology · doi:10.1016/j.jddst.2020.101734 · Cited by 27
Yang, L., Gu, J., Luan, T., Qiao, X., Cao, Y., Xue, C., & Xu, J. (2020) · Journal of the Science of Food and Agriculture · doi:10.1002/jsfa.10780 · Cited by 27
Synergistic Computational Modeling Approaches as Team Players in the Game of Solubility Predictions
Kuentz, M., & Bergström, C. A. S. (2020) · Journal of Pharmaceutical Sciences · doi:10.1016/j.xphs.2020.10.068 · Cited by 27
Ravi, P. R., & Vats, R. (2017) · Journal of Pharmacy and Pharmacology · doi:10.1111/jphp.12716 · Cited by 27
“In addition, SLNs are reported to be taken up into the lymphatic circulation system during the oral absorption process and thus directly gain access to HIV reservoir sites.([12,16]) Unlike conventional formulations, in any drug-loaded nanocarrier system, the plasma drug exposure is controlled mostly by carrier system…”
BackgroundClark, S. O., Cross, M. L., Nadian, A. K., Vipond, J., Court, P., Williams, A., Hewinson, R. G., Aldwell, F. E., & Chambers, M. A. (2008) · Infection and Immunity · doi:10.1128/iai.00052-08 · Cited by 27
Griffin, B. T., & O’Driscoll, C. M. (2007) · Springer eBooks · doi:10.1007/978-0-387-74901-3_2 · Cited by 27
“Studies of the uptake and transport of drugs into the body via the intestinal lymphatics have received increasing attention in recent years [79, 80].”
BackgroundQelliny, M. R., Mustafa, W. W., Fatease, A. M. A., Alamri, A. H., Alany, R. G., & Abdelkader, H. (2025) · Pharmaceutics · doi:10.3390/pharmaceutics17050598 · Cited by 26
“Lipid-based excipients, derived from vegetable oils, fatty acids, or waxes, include triacylglycerols, phospholipids, and lipophilic vitamins [63,64].”
Borkar, N., Holm, R., Yang, M., Müllertz, A., & Mu, H. (2016) · International Journal of Pharmaceutics · doi:10.1016/j.ijpharm.2016.09.024 · Cited by 26
Engineering intelligent particle-lipid composites that control lipase-mediated digestion
Joyce, P. M., Gustafsson, H., & Prestidge, C. A. (2018) · Advances in Colloid and Interface Science · doi:10.1016/j.cis.2018.08.001 · Cited by 26
Khatri, H. N., Chokshi, N. V., Rawal, S. U., Patel, B. M., Badanthadka, M., & Patel, M. M. (2020) · International Journal of Pharmaceutics · doi:10.1016/j.ijpharm.2020.119386 · Cited by 26
Introduction to Nanoscience, Nanotechnology and Nanoparticles
Mandal, A., & Banerjee, E. R. (2020) · Springer eBooks · doi:10.1007/978-981-15-5274-8_1 · Cited by 26
Sailor, G. U. (2021) · Springer eBooks · doi:10.1007/978-981-33-4497-6_10 · Cited by 26
Rice bran wax structured oleogels and in vitro bioaccessibility of curcumin
Dent, T., Hallinan, R., Chitchumroonchokchai, C., & Maleky, F. (2022) · Journal of the American Oil Chemists Society · doi:10.1002/aocs.12576 · Cited by 26
Reed, A. L., Rowson, S. A., & Dixon, J. B. (2013) · Pharmaceutical Research · doi:10.1007/s11095-013-1218-x · Cited by 26
“Approaches with oral delivery to lymphatics have been fundamentally similar to that of the interstitium, targeting either immune cells residing in gut lymphoid tissue (21) or targeting the incorporation of the drug into chylomicrons, which are then taken up exclusively by lymphatics (17,22).”
BackgroundTechnological Means to Modulate Food Digestion and Physiological Response
Donato, L., García‐Ródenas, C. L., Pouteau, E. B., Lehmann, U., Srichuwong, S., Erkner, A., Kolodziejczyk, E., Hughes, E., Wooster, T. J., & Sagalowicz, L. (2014) · Elsevier eBooks · doi:10.1016/b978-0-12-404610-8.00014-1 · Cited by 26
Ali, H., Verma, P. R. P., Dubey, S. K., Venkatesan, J., Seo, Y., Kim, S., & Singh, S. K. (2017) · RSC Advances · doi:10.1039/c7ra04038e · Cited by 26
Shan, W., Cui, Y., Liu, M., Wu, L., Xiang, Y., Guo, Q., Zhang, Z., & Huang, Y. (2017) · International Journal of Pharmaceutics · doi:10.1016/j.ijpharm.2017.07.061 · Cited by 26
He, Y., Zhan, C., Pi, C., Zuo, Y., Yang, S., Hu, M. L., Bai, Y. B., Zhao, L., & Wei, Y. (2020) · AAPS PharmSciTech · doi:10.1208/s12249-020-01711-2 · Cited by 26
Bioavailability and Delivery of Nutraceuticals and Functional Foods Using Nanotechnology
Yu, H., & Huang, Q. (2013) · Wiley eBooks · doi:10.1002/9781118451915.ch35 · Cited by 26
Influence of bile on the absorption of halofantrine from lipid-based formulations
Holm, R., Tønsberg, H., Jørgensen, E. B., Abedinpour, P., Farsad, S., & Müllertz, A. (2012) · European Journal of Pharmaceutics and Biopharmaceutics · doi:10.1016/j.ejpb.2012.03.005 · Cited by 26
Recent developments in oral lipid-based drug delivery
Thomas, N., Rades, T., & Müllertz, A. (2013) · Journal of Drug Delivery Science and Technology · doi:10.1016/s1773-2247(13)50054-2 · Cited by 26
A study on the inhibitory mechanism for cholesterol absorption by α-cyclodextrin administration
Furune, T., Ikuta, N., Ishida, Y., Okamoto, H., Nakata, D., Terao, K., & Sakamoto, N. (2014) · Beilstein Journal of Organic Chemistry · doi:10.3762/bjoc.10.300 · Cited by 25
Veeravalli, V., Cheruvu, H. S., Srivastava, P., & Madgula, L. M. V. (2020) · Journal of Pharmaceutical Analysis · doi:10.1016/j.jpha.2020.02.007 · Cited by 26
A Literature Review on Self Nanoemulsifying Drug Delivery System (SNEDDS)
Saikumar, D., & Jonnalagadda, L. P. (2021) · International Journal of Pharmaceutical Sciences Review and Research · doi:10.47583/ijpsrr.2021.v70i01.011 · Cited by 25
Lin, Y., McClements, D. J., Xiao, J., Cao, Y., & Liu, X. (2022) · Journal of Agricultural and Food Chemistry · doi:10.1021/acs.jafc.2c05836 · Cited by 25
Guruge, A. G., Warren, D. B., Pouton, C. W., & Chalmers, D. K. (2023) · Molecular Pharmaceutics · doi:10.1021/acs.molpharmaceut.3c00049 · Cited by 25
Yu, H., Kim, C.-Y., & Chang, P. (2023) · Food Chemistry · doi:10.1016/j.foodchem.2023.137927 · Cited by 25
Pivette, P., Faivre, V., Daste, G., Ollivon, M., & Lesieur, S. (2009) · Journal of Thermal Analysis and Calorimetry · doi:10.1007/s10973-009-0348-1 · Cited by 25
“ment of their bioavailability can be achieved by their coadministration with lipid-based excipients [1].”
BackgroundQuantifying exploratory low dose compounds in humans with AMS
Dueker, S. R., Vuong, L. T., Lohstroh, P. N., Giacomo, J., & Vogel, J. S. (2010) · Advanced Drug Delivery Reviews · doi:10.1016/j.addr.2010.10.009 · Cited by 25
“Lymphatic transport and delivery as a prodrug are two strategic options that avoid first pass hepatic metabolism and alter clearance and deposition [45-46].”
BackgroundBéaslas, O., Torreilles, F., Casellas, P., Simon, D., Fabre, G., Lacasa, M., Delers, F., Chambaz, J., Rousset, M., & Carrière, V. (2008) · American Journal of Physiology-Gastrointestinal and Liver Physiology · doi:10.1152/ajpgi.90237.2008 · Cited by 25
Yao, X., Zhang, W., Nie, K., Gao, Z., Fang, Y., Nishinari, K., Phillips, G. O., & Jiang, F. (2016) · Food Biophysics · doi:10.1007/s11483-016-9441-8 · Cited by 25
Dalvadi, H., Patel, N., & Parmar, K. R. (2017) · Journal of Microencapsulation · doi:10.1080/02652048.2017.1324920 · Cited by 25
“…(Hauss et al., 1998; McClements et al., 2007; Karasulu, 2008), solid dispersion (Nagabandi et al., 2014), self-microemulsifying drug delivery system ( Porter et al., 2007; Pouton and Porter, 2008; Mu et al., 2013) and liposomes (Martins et al., 2007; Patel and Sawant, 2007; Jain et al., 2014).”
BackgroundKoziolek, M., Kostewicz, E. S., & Vertzoni, M. (2018) · AAPS PharmSciTech · doi:10.1208/s12249-018-1159-0 · Cited by 25
Lee, Y., & Choi, S. Q. (2019) · European Journal of Pharmaceutical Sciences · doi:10.1016/j.ejps.2019.04.020 · Cited by 25
The Prospects of Lipidic Prodrugs: An Old Approach with an Emerging Future
Dahan, A., Marković, M., Aponick, A., Zimmermann, E. M., & Ben‐Shabat, S. (2019) · Future Medicinal Chemistry · doi:10.4155/fmc-2019-0155 · Cited by 25
Hempt, C., Gontsarik, M., Buerki‐Thurnherr, T., Hirsch, C., & Salentinig, S. (2020) · Journal of Colloid and Interface Science · doi:10.1016/j.jcis.2020.04.059 · Cited by 25
Cecchi, L., Piazzini, V., D’Ambrosio, M., Luceri, C., Rocco, F. D., Innocenti, M., Vanti, G., Mulinacci, N., & Bergonzi, M. C. (2020) · Molecules · doi:10.3390/molecules25143198 · Cited by 25
Chokshi, N. V., Rawal, S. U., Solanki, D., Gajjar, S., Bora, V. R., Patel, B. M., & Patel, M. M. (2021) · Journal of Pharmaceutical Sciences · doi:10.1016/j.xphs.2021.02.018 · Cited by 25
Sailor, G. U., Vinod, R., Shah, N. V., Parmar, G. R., Gohil, D., Balaraman, R., & Seth, A. K. (2021) · Indian Journal of Pharmaceutical Sciences · doi:10.36468/pharmaceutical-sciences.766 · Cited by 25
“The reason for this improvement in bioavailability may be due to the ability of lipid-based formulations to reach the oral lymphatic region after absorption and reaching to systemic circulation[21,63-65].”
BackgroundKoehl, N. J., Henze, L. J., Bennett-Lenane, H., Faisal, W., Price, D. J., Holm, R., Kuentz, M., & Griffin, B. T. (2021) · Molecular Pharmaceutics · doi:10.1021/acs.molpharmaceut.0c00645 · Cited by 25
Solvent-free drug crystal engineering for drug nano- and micro suspensions
Antunes, A. B. D. F., Geest, B. G. D., Vervaet, C., & Remon, J. P. (2012) · European Journal of Pharmaceutical Sciences · doi:10.1016/j.ejps.2012.10.017 · Cited by 25
Modeling Free Energies of Solvation in Olive Oil
Chamberlin, A. C., Levitt, D. G., Cramer, C. J., & Truhlar, D. G. (2008) · Molecular Pharmaceutics · doi:10.1021/mp800059u · Cited by 25
Food Structure Engineering for Nutrition, Health and Wellness
Kaufmann, S. F. M., & Palzer, S. (2013) · Food engineering series · doi:10.1007/978-1-4614-7906-2_20 · Cited by 25
“, “oral administration” in pharmaceutical terms), this dictates, that the active substance must first dissolve within the gastrointestinal tract before partitioning into and then across the enterocyte [12].”
BackgroundChristiansen, A., Backensfeld, T., Kühn, S., & Weitschies, W. (2011) · Journal of Pharmaceutical Sciences · doi:10.1002/jps.22408 · Cited by 25
White, K. L., Nguyen, G., Charman, W. N., Edwards, G. A., Faassen, W. A., & Porter, C. J. H. (2009) · Journal of Pharmacology and Experimental Therapeutics · doi:10.1124/jpet.109.154542 · Cited by 25
“Mechanisms by which increased drug absorption can occur include slowing of gastric emptying, enhancement of gastrointestinal dissolution or solubilization, protection from intestinal degradation, and stimulation of lymphatic drug transport (Charman et al., 1997; Wasan, 2001; Grove et al., 2007; Porter et al., 2007; Da…”
BackgroundSelf-citationMun, S., & McClements, D. J. (2017) · LWT · doi:10.1016/j.lwt.2017.02.011 · Cited by 25
Li, W., Wang, W., Yong, C., Lan, Y., Huang, Q., & Xiao, J. (2022) · Journal of Agricultural and Food Chemistry · doi:10.1021/acs.jafc.1c07987 · Cited by 24
Koilpillai, J., & Narayanasamy, D. (2022) · Journal of Liposome Research · doi:10.1080/08982104.2022.2069809 · Cited by 24
“LBDDS are subjected to GI processing after gastric emptying, which includes dispersion, digestion, and bile mixing (Porter et al. 2007).”
Wu, F., Wang, D.-D., Wen, M., Che, H.-X., Xue, C.-H., Yanagita, T., Zhang, T.-T., & Wang, Y.-M. (2017) · Lipids in Health and Disease · doi:10.1186/s12944-017-0623-2 · Cited by 20
“phospholipase A2 mediated partial hydrolysis [25].”
Metadata
- Authors
- Porter, C. J. H., Trevaskis, N. L., & Charman, W. N.
- Affiliations
- Monash University (AU)
- Corresponding author
- Porter, Christopher J. H.
- Venue
- Nature Reviews Drug Discovery
- Published
- 2007-03
- Volume
- 6
- Issue
- 3
- Pages
- 231-248
- ISSN
- 1474-1776 (ISSN-L)
- 1474-1784
- OpenAlex
- W2069235788
- Cited by
- 1,824
- References
- 253
- Citations by year
- 2026: 88 · 2025: 87 · 2024: 67 · 2023: 89 · 2022: 119 · 2021: 108 · 2020: 140 · 2019: 101 · 2018: 117 · 2017: 121 · 2016: 125 · 2015: 119 · 2014: 120 · 2013: 128 · 2012: 94
- FWCI
- 4.11
- Type
- journal article
- Language
- en
- Open access
- closed
- Licence
- www.springer.com/tdm (tdm)
- Locations
- Nature Reviews Drug Discovery (publishedVersion)
- PubMed (publishedVersion)
- Topics
- Life Sciences › Pharmacology, Toxicology and Pharmaceutics › Pharmaceutical Science › Drug Solubulity and Delivery Systems
- Life Sciences › Pharmacology, Toxicology and Pharmaceutics › Pharmaceutical Science › Advanced Drug Delivery Systems
- Health Sciences › Medicine › Oncology › Drug Transport and Resistance Mechanisms
- Keywords
- lipid-based drug delivery, oral bioavailability, lipophilic drugs, poorly water-soluble drugs, lipid excipients, first-pass metabolism, lipid-based formulations
- MeSH terms
- Administration, Oral, Animals, Pharmaceutical Preparations, Excipients, Humans, Intestinal Absorption, Lipids, Drug Design, Drug Delivery Systems, Hydrophobic and Hydrophilic Interactions
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.